THERAPIES
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
-
Hemophilia B gene therapy approved by U.S. FDA
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
-
No change to factor IX product mix in Quebec
Montreal, August 15, 2022 – On July 15, Héma-Québec announced the results of the recombinant factor IX tender for the period from October 1, 2022...
-
The FactorFirst card has been revised
The highly popular and useful FactorFirst card has been revised and the new version is now available for orders! Thank you to a great team...